BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37844295)

  • 1. A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
    McLoughlin DE; Chevalier N; Choy E; Cote GM; Gao X; Juric D; Reynolds KL
    Oncologist; 2023 Dec; 28(12):1094-1099. PubMed ID: 37844295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
    Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.
    Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Ren ZL; Zhang JJ; Liu SW; Yu L; Li YL
    Acta Pharmacol Sin; 2022 Sep; 43(9):2397-2409. PubMed ID: 35165399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
    Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
    Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
    Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic utility of S100A1, GLUT-1 and Caveolin-1 in renal tumors with oncocytic features: a comparative study].
    Zhang W; Wang K; Yu W; Liu Y; Chu J; Jiang Y; Li Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Nov; 44(11):767-71. PubMed ID: 26888385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
    Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
    Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.
    Pwint TP; Macaulay V; Roberts IS; Sullivan M; Protheroe A
    Urol Oncol; 2011; 29(6):821-4. PubMed ID: 19962921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
    Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
    Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prospect of precision therapy for renal cell carcinoma.
    Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
    Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic pitfall of a rare variant of angiomyolipoma, epithelioid angiomyolipoma - a case report.
    Anthony ML; Durgapal P; Joshi P; Mittal A; Sahai R; Kishore S; Singh A
    Pan Afr Med J; 2020; 37():210. PubMed ID: 33505578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.